This site uses Google Analytics for tracking site performance.
Properly executed Market Access and HEOR will add value throughout the product life cycle. We offer the full complement of services using innovative and tested methodologies designed to deliver results.
From early phase asset evaluation and clinical trial input to mature products and tenders, Initiate will select the appropriate tools and methods to shape optimal market access and HEOR.
The team at Initiate just get on with it! That makes life very easy for me, knowing that your expertise will help me to achieve.
General Manager, top 20 Pharma
We hired you to help us through a short-term hiatus in resource. You picked up the project and owned it, feeling everything personally. You delivered way ahead of expectations. We will use your team again and again. Thank you!
Global Director, Market Access
We don’t have in-house market access teams because Initiate can provide such great support. The team amazed us with their ideas and approaches to creating a model that shows cost effectiveness.
General Manager, EU Pharma
The modified Delphi work was crucial in setting the scene and closing the deal on positioning this product. We felt we were starting in a position of risk of failure until the authority accepted the modified Delphi, without which we would not have had a positive recommendation.
Market Access Director, top 10 Pharmaceutical Company
Until now, we didn’t have the frameworks in place to ensure co-creation and ownership for affiliate teams. Your work with all stakeholders has been transformational – we can now focus on the right things for our launches, knowing that we are all aligned on pricing and process.
VP Global Commercial Operations, Oncology Speciality Biotech Company
You are the 3rd agency to try to achieve reimbursement for this product and have succeeded where others have failed. Because of your ability to simplify the situation and make the payers more pragmatic, a number of people in this country will now have a chance to extend their life. Thank you.”
Market Access Director, EU Pharma
Your Asset Evaluation has allowed our board to enter into a deal (to In-license) with real confidence for this product.
Business Development Director, Global Pharma
Our expertise is built upon long-standing client partnership with global pharmaceutical, biotech, device and diagnostic companies where we are delivering with purpose.